|Bid||42.02 x 800|
|Ask||44.15 x 800|
|Day's range||43.72 - 44.86|
|52-week range||27.85 - 48.50|
|Beta (5Y monthly)||1.15|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||54.00|
Strong sales of Orthofix's (OFIX) M6-C artificial disc and FITBONE lengthening nail drive its Q1 top line.
Joining me on the call today are our President and Chief Executive Officer, Jon Serbousek; and Chief Financial Officer, Doug Rice. During this call, we will be making forward-looking statements that involve risks and uncertainties.
Orthofix (OFIX) delivered earnings and revenue surprises of 142.86% and 10.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?